References
- Stevanato Group unveils on-body drug delivery device. www.drugdeliverybusiness.com/stevanato-group-unveils-drug-delivery-device/
- Stevanato Group presents, a versatile on-body delivery system platform for a wide range of injectable therapies and for large delivery volumes (up to 10 ml). www.stevanatogroup.com/en/news-events/press-releases/stevanato-group-presents-vertiva/
- LTS completes its entry into large molecule drug delivery with the acquisition of the Sorrel wearable injection device business. www.prnewswire.com/news-releases/lts-completes-its-entry-into-large-molecule-drug-delivery-with-the-acquisition-of-the-sorrel-wearable-injection-device-business-301845208.html
- CD Bioparticles Announces New PLGA-Based Drug Delivery Systems for In Vitro and In Vivo Applications. www.einnews.com/pr_news/639586889/cd-bioparticles-announces-new-plga-based-drug-delivery-systems-for-in-vitro-and-in-vivo-applications
- Novo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares. www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166114
- Novo Nordisk looks to acquire a majority stake in BioCorp for $164.5 M. www.drugdeliverybusiness.com/novo-nordisk-acquire-majority-stake-biocorp/
- New UK drug delivery centre to support RNA therapeutic development. www.europeanpharmaceuticalreview.com/news/183175/new-uk-drug-delivery-centre-to-support-rna-therapeutic-development/
- Future Fields and Jenthera Therapeutics Collaborate to Develop Novel Protein for the Delivery of Cancer Biologics. www.businesswire.com/news/home/20230613873412/en/Future-Fields-and-Jenthera-Therapeutics-Collaborate-to-Develop-Novel-Protein-for-the-Delivery-of-Cancer-Biologics
- Future Fields, Jenthera Therapeutics collaborate to develop novel protein for the delivery of cancer biologics. www.scienceboard.net/index.aspx?sec=ser&sub=def&pag=dis&ItemID=5499
- Feldan Therapeutics secures $16.5m Series B to bring lead asset to clinical development. www.feldan.com/news/feldan-therapeutics-secures-16.5m-series-b-to-bring-lead-asset-to-clinical-development
- Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics. www.businesswire.com/news/home/20230606005983/en/Bayer-Strengthens-Gene-Therapy-Portfolio-With-Lipid-Nanoparticle-Technology-From-Acuitas-Therapeutics
- Croda announces two new partnerships to drive sustainable delivery systems for the pharmaceutical industry. https://pharmaceuticalmanufacturer.media/pharma-manufacturing-news/pharma-finance-and-investment-news/croda-announces-two-new-partnerships-to-drive-sustainable-de/
- Croda breaks ground on new manufacturing facility for pharmaceutical excipients. www.croda.com/en-gb/news/croda-breaks-ground-on-new-manufacturing-facility-for-pharmaceutical-excipients
- Nanoform and Celanese Demonstrate Enhanced Drug Delivery through the Power of Smaller Implants. https://nanoform.com/en/nanoform-and-celanese-demonstrate-enhanced-drug-delivery-through-the-power-of-smaller-implants/
- Nanoform, Celanese Demonstrate Enhanced Drug Delivery Technology. www.contractpharma.com/contents/view_breaking-news/2023-06-15/nanoform-celanese-demonstrate-enhanced-drug-delivery-technology/
- Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis. www.prnewswire.com/news-releases/halozyme-announces-argenx-receives-fda-approval-for-vyvgart-hytrulo-with-enhanze-for-subcutaneous-use-in-generalized-myasthenia-gravis-301855994.html
- Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon. https://surmodics.gcs-web.com/news-releases/news-release-details/surmodics-receives-fda-approval-surveiltm-drug-coated-balloon
- New data show once-weekly insulin icodec met additional endpoints in adults with type 2 diabetes in phase 3a trials. www.prnewswire.com/news-releases/new-data-show-once-weekly-insulin-icodec-met-additional-endpoints-in-adults-with-type-2-diabetes-in-phase-3a-trials-301862521.html
- Once-weekly insulin from Novo Nordisk meets clinical trial endpoints. www.drugdeliverybusiness.com/once-weekly-insulin-novo-nordisk-meets-endpoints/
- Sernova Announces Positive Updated Interim Phase I/2 Clinical Data for the Cell Pouch System™ at American Diabetes Association 83rd Scientific Sessions. www.drugdeliverybusiness.com/sernova-interim-data-cell-pouch-system/
- Pulmatrix Presents PUR3100 Phase I Data at the 65th Annual Meeting of the American Headache Society. www.prnewswire.com/news-releases/pulmatrix-presents-pur3100-phase-1-data-at-the-65th-annual-meeting-of-the-american-headache-society-301852038.html
- Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen). www.prnewswire.com/news-releases/alcyone-therapeutics-receives-fda-ide-approval-to-initiate-clinical-study-of-the-thecaflex-drxtm-system-for-administration-of-spinraza-nusinersen-301863840.html
- Bioengineered particles expand myelin-specific regulatory T cells and reverse autoreactivity in a mouse model of multiple sclerosis. 10.1126/sciadv.add8693
- Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform. www.globenewswire.com/news-release/2023/06/28/2696172/0/en/Biora-Therapeutics-Announces-New-Patents-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html
- Cognigenics' Intranasal CRISPR Delivery Bypasses Blood-Brain Barrier; Potential Breakthrough Therapeutic. www.businesswire.com/news/home/20230622275874/en/Cognigenics-Intranasal-CRISPR-Delivery-Bypasses-Blood-Brain-Barrier-Potential-Breakthrough-Therapeutic
- Rohn TT , RadinD, BrandmeyerTet al. Genetic modulation of the HTR2A gene reduces anxiety-related behavior in mice. PNAS Nexus2(6), 170 (2023).
- CraniUS obtains scientific evidence of successful convection-enhanced delivery using patented NeuroPASS device. www.prnewswire.com/news-releases/cranius-obtains-scientific-evidence-of-successful-convection-enhanced-delivery-using-patented-neuropass-device-301863557.html
- Ben-Akiva E , KarlssonJ, HemmatiAet al. Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination. Proc. Natl Acad. Sci. USA120(26), e2301606120 (2023).
- New nanoparticle could improve the delivery of mRNA-based vaccines. www.news-medical.net/news/20230628/New-nanoparticle-could-improve-the-delivery-of-mRNA-based-vaccines.aspx